Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
Rimiducid is a tacrolimus analogue drug that contains an analogue of FKBP12, which allows homodimerization of genetically engineered receptors containing an FKBP12 binding domain, thereby, inducing apoptosis when necessary (NCI Drug Dictionary).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Rimiducid||AP1903||Rimiducid is a tacrolimus analogue drug that contains an analogue of FKBP12, which allows homodimerization of genetically engineered receptors containing an FKBP12 binding domain, thereby, inducing apoptosis when necessary (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02487459||Phase I||BPX-501 Rimiducid||Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies||Withdrawn|
|NCT02477878||Phase I||BPX-601 Rimiducid||Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant||Active, not recruiting|
|NCT03807063||Phase I||Rimiducid BPX-501||Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant||Suspended|
|NCT02786485||Phase I||Rimiducid BPX-501||Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT||Withdrawn|
|NCT02065869||Phase Ib/II||BPX-501 Rimiducid||Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant||Active, not recruiting|
|NCT02792114||Phase I||Rimiducid Mesothelin CAR-T cells Cyclophosphamide||T-Cell Therapy for Advanced Breast Cancer||Recruiting|
|NCT02743611||Phase I||Rimiducid BPX-701||Dose Finding Study Evaluating Safety and Feasibility in Patients With Relapsed or Refractory Myeloid Neoplasms||Active, not recruiting|
|NCT01744223||Phase Ib/II||Rimiducid BPX-501||Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant||Active, not recruiting|
|NCT03696784||Phase I||Rimiducid Bendamustine + Fludarabine + iC9/CAR.19/IL15-Transduced CB-NK||Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma||Recruiting|
|NCT04249947||Phase I||P-PSMA-101 CAR-T cells Rimiducid||P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)||Recruiting|
|NCT03741127||Phase I||Rimiducid||Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101||Enrolling by invitation|
|NCT03958656||Phase I||Anti-SLAMF7 CAR T cells + Cyclophosphamide + Fludarabine Rimiducid||T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma||Recruiting|